British Journal of Clinical Pharmacology: Introduction

British Journal of Clinical Pharmacology

Volumn 53, Issue SUPPL. 1, 2002, Pages

  Edwards, Geoffrey ^a   Muirhead, Gary J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Bioavailability; Phamiacokinetics; Pharmacodynnmics; Sildenafil

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V; PLACEBO; SILDENAFIL;

CORPUS CAVERNOSUM; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EDITORIAL; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; NOSE CONGESTION; PENIS ERECTION; PRIORITY JOURNAL; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

EID: 28244434361     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.00026.x     Document Type: Editorial

References (9)

1. Goldstein I, Lue TF, Padim-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
2. Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen RC. Sildenafil citrate (Viagra®) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800-805.
3. TM) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74.
4. McMahon CG, Samali R, Johnson H. Efficacy, safety, and patient acceptance of sildenafil as treatment for erectile dysfunction. J Urol 2000; 164: 1192-1196.
5. Marks LS, Duda C, Dorey FJ. Treatment of erectile dysfunction with sildenafil. Urology 1999; 53: 19-24.
6. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res 1996; 8: 47-52.
7. Ballard S, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase enzymes. J Urol 1998; 159: 2164-2171.
8. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C.
9. Muirhead G, Wulff MB, Fielding A, Kleinennans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Dr J Clin Pharmacol 2000; 50: 99-107.